Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
Scinai Immunotherapeutics Ltd (SCNI) - Total Assets
Latest total assets as of June 2025: $11.84 Million USD
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) holds total assets worth $11.84 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scinai Immunotherapeutics Ltd - Total Assets Trend (2000–2024)
This chart illustrates how Scinai Immunotherapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Scinai Immunotherapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Scinai Immunotherapeutics Ltd's total assets of $11.84 Million consist of 17.8% current assets and 82.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.6% |
| Accounts Receivable | $217.00K | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Scinai Immunotherapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scinai Immunotherapeutics Ltd's current assets represent 17.8% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, down from 100.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Scinai Immunotherapeutics Ltd Competitors by Total Assets
Key competitors of Scinai Immunotherapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Scinai Immunotherapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Scinai Immunotherapeutics Ltd generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Scinai Immunotherapeutics Ltd generates $ 35.66 in net profit.
Scinai Immunotherapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 2.19 | 2.48 |
| Quick Ratio | 0.71 | 2.19 | 2.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-614.00K | $ 1.99 Million | $ 4.83 Million |
Scinai Immunotherapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Scinai Immunotherapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -23.0% |
| Total Assets | $13.45 Million |
| Market Capitalization | $2.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scinai Immunotherapeutics Ltd's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scinai Immunotherapeutics Ltd's assets decreased by 23.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scinai Immunotherapeutics Ltd (2000–2024)
The table below shows the annual total assets of Scinai Immunotherapeutics Ltd from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.45 Million | -23.03% |
| 2023-12-31 | $17.47 Million | -35.45% |
| 2022-12-31 | $27.07 Million | -15.51% |
| 2021-12-31 | $32.04 Million | +80.93% |
| 2020-12-31 | $17.71 Million | -47.17% |
| 2019-12-31 | $33.52 Million | +18.43% |
| 2018-12-31 | $28.30 Million | +20.54% |
| 2017-12-31 | $23.48 Million | +200.42% |
| 2016-12-31 | $7.82 Million | -26.28% |
| 2015-12-31 | $10.60 Million | +123.73% |
| 2014-12-31 | $4.74 Million | -36.37% |
| 2013-12-31 | $7.45 Million | +19.63% |
| 2012-12-31 | $6.22 Million | -13.10% |
| 2011-12-31 | $7.16 Million | -17.47% |
| 2010-12-31 | $8.68 Million | -3.02% |
| 2009-12-31 | $8.95 Million | +179.92% |
| 2008-12-31 | $3.20 Million | +440.12% |
| 2007-12-31 | $592.00K | -70.16% |
| 2006-12-31 | $1.98 Million | -40.69% |
| 2005-12-31 | $3.35 Million | -35.05% |
| 2004-12-31 | $5.15 Million | +110.63% |
| 2003-12-31 | $2.44 Million | +43.65% |
| 2002-12-31 | $1.70 Million | +170100.00% |
| 2001-12-31 | $1.00K | -66.67% |
| 2000-12-31 | $3.00K | -- |